Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FULC Fulcrum Therapeutics	$2.51 -1.6%	$3.42	$2.41 ▼ $10.13	$135.49M	2.13	946,134 shs	346,346 shs
KRRO Korro Bio	$14.38 -2.5%	$26.41	$13.62 ▼ $98.00	$135.01M	2.31	90,970 shs	73,494 shs
MRMD MariMed	$0.09 -13.4%	$0.11	$0.07 ▼ $0.34	$33.04M	2.75	399,032 shs	1.75 million shs
NMRA Neumora Therapeutics	$0.74 -13.3%	$1.52	$0.71 ▼ $17.19	$119.30M	2.59	1.46 million shs	1.78 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FULC Fulcrum Therapeutics	-9.89%	-17.48%	-22.02%	-49.80%	-72.07%
KRRO Korro Bio	-14.94%	-19.75%	-32.31%	-65.57%	-81.08%
MRMD MariMed	+0.32%	-4.65%	-14.27%	-26.79%	-64.51%
NMRA Neumora Therapeutics	-9.72%	-22.82%	-39.79%	-60.88%	-93.62%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FULC Fulcrum Therapeutics	1.1381 of 5 stars	3.1	1.0	0.6	1.7	0.6
KRRO Korro Bio	1.354 of 5 stars	3.6	1.0	1.8	0.0	0.6
MRMD MariMed	0.7047 of 5 stars	0.0	5.0	0.6	0.8	0.6
NMRA Neumora Therapeutics	2.9334 of 5 stars	4.1	1.0	1.7	3.3	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FULC Fulcrum Therapeutics	2.11	Hold	$8.63	243.63% Upside
KRRO Korro Bio	3.17	Buy	$136.33	848.08% Upside
MRMD MariMed	4.00	Strong Buy	N/A	N/A
NMRA Neumora Therapeutics	2.22	Hold	$9.29	1,160.79% Upside

Current Analyst Ratings Breakdown

Latest MRMD, KRRO, FULC, and NMRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/3/2025	MRMD MariMed	Noble Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/2/2025	NMRA Neumora Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Underperform	$7.00 ➝ $1.00
3/20/2025	KRRO Korro Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$115.00 ➝ $115.00
3/19/2025	KRRO Korro Bio	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$105.00 ➝ $95.00
3/10/2025	NMRA Neumora Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
3/7/2025	NMRA Neumora Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
3/7/2025	NMRA Neumora Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$6.00 ➝ $2.00
3/4/2025	NMRA Neumora Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform	$4.00 ➝ $4.00
3/4/2025	NMRA Neumora Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $18.00
3/4/2025	NMRA Neumora Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
2/26/2025	FULC Fulcrum Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$4.00 ➝ $4.00

(Data available from 4/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FULC Fulcrum Therapeutics	$80M	1.69	N/A	N/A	$3.80 per share	0.66
KRRO Korro Bio	$2.27M	59.45	N/A	N/A	$21.19 per share	0.68
MRMD MariMed	$148.60M	0.22	$0.02 per share	5.59	$0.19 per share	0.46
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	$3.07 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FULC Fulcrum Therapeutics	-$97.33M	-$0.22	N/A	N/A	N/A	N/A	-7.31%	-6.74%	5/12/2025 (Estimated)
KRRO Korro Bio	-$81.17M	-$9.39	N/A	N/A	N/A	N/A	-50.25%	-38.48%	5/13/2025 (Estimated)
MRMD MariMed	-$16.03M	-$0.02	N/A	∞	N/A	-10.97%	-2.75%	-1.06%	5/6/2025 (Estimated)
NMRA Neumora Therapeutics	-$235.93M	-$1.53	N/A	N/A	N/A	N/A	-73.63%	-68.97%	5/6/2025 (Estimated)

Latest MRMD, KRRO, FULC, and NMRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
3/18/2025	Q4 2024	KRRO Korro Bio	-$2.33	-$2.26	+$0.07	-$2.26	N/A	$2.27 million
3/6/2025	Q4 2024	NMRA Neumora Therapeutics	-$0.46	-$0.37	+$0.09	-$0.37	N/A	N/A
3/5/2025	Q4 2024	MRMD MariMed	-$0.01	-$0.01	N/A	-$0.02	$42.00 million	$39.00 million
2/25/2025	Q4 2024	FULC Fulcrum Therapeutics	-$0.28	-$0.31	-$0.03	-$0.31	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FULC Fulcrum Therapeutics	N/A	N/A	N/A	N/A	N/A
KRRO Korro Bio	N/A	N/A	N/A	N/A	N/A
MRMD MariMed	N/A	N/A	N/A	N/A	N/A
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FULC Fulcrum Therapeutics	N/A	18.44	18.44
KRRO Korro Bio	N/A	11.23	11.23
MRMD MariMed	1.01	1.55	0.73
NMRA Neumora Therapeutics	N/A	10.98	10.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FULC Fulcrum Therapeutics	89.83%
KRRO Korro Bio	13.18%
MRMD MariMed	0.18%
NMRA Neumora Therapeutics	47.65%

Insider Ownership

Company	Insider Ownership
FULC Fulcrum Therapeutics	4.10%
KRRO Korro Bio	5.40%
MRMD MariMed	18.99%
NMRA Neumora Therapeutics	26.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FULC Fulcrum Therapeutics	100	53.98 million	51.73 million	Optionable
KRRO Korro Bio	70	9.39 million	8.86 million	No Data
MRMD MariMed	260	381.49 million	301.65 million	Not Optionable
NMRA Neumora Therapeutics	108	161.98 million	118.91 million	Optionable

MRMD, KRRO, FULC, and NMRA Headlines

Recent News About These Companies

Class Action Filed Against Neumora Therapeutics, Inc. (NMRA) - April 7, 2025 Deadline to Join - Contact Levi & Korsinsky

April 4 at 4:30 PM | accessnewswire.com

NMRA Deadline: NMRA Investors with Losses in Excess of $100K Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Lawsuit First Filed by The Firm

April 4 at 4:18 PM | prnewswire.com

Shareholders That Lost Money on Neumora Therapeutics, Inc. (NMRA) Should Contact Levi & Korsinsky About Pending Class Action - NMRA

April 4 at 2:00 PM | accessnewswire.com

NMRA Deadline in 3 Days: Kessler Topaz Meltzer & Check, LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors of Filing Deadline in Class Action Lawsuit

April 4 at 1:30 PM | accessnewswire.com

Neumora Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Neumora Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 - NMRA

April 4 at 1:15 PM | accessnewswire.com

Neumora Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA

April 4 at 10:25 AM | accessnewswire.com

Neumora Therapeutics' (NMRA) "Underperform" Rating Reaffirmed at Bank of America

April 4 at 8:35 AM | marketbeat.com

Class Action Filed Against Neumora Therapeutics, Inc. (NMRA) - April 7, 2025 Deadline to Join - Contact Levi & Korsinsky

April 4 at 7:25 AM | accessnewswire.com

NMRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of Neumora Therapeutics, Inc. to Contact the Firm Today!

April 4 at 7:00 AM | accessnewswire.com

Levi & Korsinsky Reminds Neumora Therapeutics, Inc. ...

April 4 at 6:12 AM | gurufocus.com

Levi & Korsinsky Reminds Neumora Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 - NMRA

April 4 at 5:45 AM | prnewswire.com

Neumora Therapeutics (NASDAQ:NMRA) Receives "Underperform" Rating from Bank of America

April 4 at 2:48 AM | americanbankingnews.com

Shareholders that Lost Money on Neumora Therapeutics, Inc. (NMRA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

April 3 at 7:30 PM | accessnewswire.com

NMRA Investors Have Opportunity to Lead Neumora Therapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

April 3 at 7:10 PM | prnewswire.com

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 7, 2025 in Neumora Therapeutics, Inc. Lawsuit - NMRA

April 3 at 4:15 PM | accessnewswire.com

Neumora Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your ...

April 3 at 4:00 PM | gurufocus.com

Neumora Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 7, 2025 Deadline to file Lead Plaintiff Motion.

April 3 at 3:56 PM | globenewswire.com

Contact Levi & Korsinsky by April 7, 2025 Deadline to Join Class Action Against Neumora Therapeutics, Inc. (NMRA)

April 3 at 2:30 PM | accessnewswire.com

NMRA FINAL DEADLINE: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Neumora Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action First Filed by the Firm – NMRA

April 3 at 2:12 PM | globenewswire.com

NMRA IMPORTANT DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action First Filed by the Firm - NMRA

April 3 at 1:48 PM | accessnewswire.com

Shareholders of Neumora Therapeutics, Inc. Should Contact The Gross Law Firm Before April 7, 2025 to Discuss Your Rights – NMRA

April 3 at 1:05 PM | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRMD, KRRO, FULC, and NMRA Company Descriptions

Fulcrum Therapeutics NASDAQ:FULC

$2.51 -0.04 (-1.57%)

Closing price 04:00 PM Eastern

Extended Trading

$2.50 0.00 (-0.20%)

As of 04:05 PM Eastern

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Korro Bio NASDAQ:KRRO

$14.38 -0.37 (-2.51%)

Closing price 04:00 PM Eastern

Extended Trading

$14.46 +0.08 (+0.59%)

As of 04:05 PM Eastern

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

MariMed OTCMKTS:MRMD

$0.09 -0.01 (-13.40%)

As of 03:55 PM Eastern

MariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature's Heritage brand; and soft and chewy baked goods and a hot chocolate mix under Bubby's Baked brand; and drink mix under Vibations brand. It also offers chewable cannabis-infused mint tablet under the brand Kalm Fusion; and flower, vapes, and edibles under InHouse brand. In addition, the company provides supplement, nutrient-infused fruit chews under Betty's Eddies brand and ice creams under Emack & Bolio's brand. The company licenses its brands. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts.

Neumora Therapeutics NASDAQ:NMRA

$0.74 -0.11 (-13.25%)

Closing price 04:00 PM Eastern

Extended Trading

$0.78 +0.04 (+5.23%)

As of 07:48 PM Eastern

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time